Multiple-Dose Pharmacokinetics of the Selective Nicotinic Receptor Partial Agonist, Varenicline, in Healthy Smokers

Varenicline is a novel and selective α4β2 nicotinic acetylcholine receptor partial agonist developed for smoking cessation. The primary objectives of this double‐blind, placebo‐controlled, dose‐escalation study were to determine the pharmacokinetics, safety, and tolerability of multiple oral doses o...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical pharmacology 2006-12, Vol.46 (12), p.1439-1448
Hauptverfasser:	Faessel, Hélène M., Gibbs, Megan A., Clark, David J., Rohrbacher, Kevin, Stolar, Marilyn, Burstein, Aaron H.
Format:	Artikel
Sprache:	eng
Schlagworte:	Acetylcholine Administration, Oral Adolescent Adult Area Under Curve Benzazepines - administration & dosage Benzazepines - adverse effects Benzazepines - pharmacokinetics Cotinine - blood Dose-Response Relationship, Drug Double-Blind Method Drug Administration Schedule Female Half-Life Headache - chemically induced Health aspects Humans Hypotension, Orthostatic - chemically induced Male Metabolic Clearance Rate Middle Aged multiple dosing Nausea - chemically induced Nicotine - blood Patient Dropouts pharmacokinetics Quinoxalines - administration & dosage Quinoxalines - adverse effects Quinoxalines - pharmacokinetics Receptors Receptors, Nicotinic - metabolism Smoking - metabolism Smoking Cessation - methods Smoking cessation products Smoking Prevention Tablets Varenicline Vomiting - chemically induced
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!